Copenhagen-based Commit Biologics has appointed veteran biotech entrepreneur Dr. Thomas L. F. Montgomery Andresen as its new Chief Executive Officer. This strategic move comes as the company prepares to transition from a preclinical to a clinical-stage organization. Dr. Andresen's leadership is expected to accelerate the development of its novel complement-activating immunotherapy platform.
A Strategic Leadership Transition
Dr. Andresen brings over two decades of experience in building high-value biotechnology ventures across Europe and the United States. His career includes co-founding Torque Therapeutics, which was acquired by Repertoire Immune Medicines, and most recently serving as founding CEO of T-Cypher Bio. He is a prolific inventor and author with a strong background in translating scientific discoveries into commercial technologies.
Anker Lundemose, Chairman of the Board at Commit Biologics, highlighted Dr. Andresen's unique qualifications for the role. He noted that the new CEO's blend of deep scientific knowledge and proven entrepreneurial leadership is ideal for guiding Commit's next growth phase. This appointment is seen as a crucial step in solidifying the company's position as an innovator in complement-targeting therapies.
Pioneering Complement-Powered Immunotherapy
Commit Biologics is developing a new class of treatments using its proprietary Bispecific Complement Engager (BiCE™) technology platform. This approach aims to activate the complement system, a powerful but underutilized part of the innate immune response, to eliminate diseased cells. The company believes this represents a major new modality in the field of immunotherapy.
The company's confidence is bolstered by recent positive proof-of-concept data from a non-human primate study announced in late 2025. The results demonstrated rapid, deep, and sustained B-cell depletion without inducing systemic cytokine release. This provided critical validation of the BiCE™ platform's efficacy and favorable safety profile ahead of human trials.
Charting a Course to the Clinic
With this validated platform, Commit is poised to nominate its first two clinical development candidates later in 2026. These initial programs will address significant unmet medical needs within the fields of autoimmune disease and oncology. The selections will mark a major milestone in the company's progression toward clinical evaluation.
The broader pipeline strategy focuses on indications where the BiCE™ platform's unique mechanism of action offers distinct advantages. This includes targeting patient populations with compromised T-cell function, where conventional immunotherapies may be less effective. This targeted approach aims to unlock new, high-value treatment possibilities for challenging diseases.
In his new role, Dr. Andresen expressed strong conviction in the company's science, calling complement-powered immune engagers the next frontier in immunotherapy. He thanked Interim CEO and Chief Scientific Officer Mikkel Wandahl Pedersen for establishing strong momentum. Dr. Andresen looks forward to working with the team to deliver life-changing therapies for patients.
The appointment of Dr. Thomas Andresen marks a pivotal moment for Commit Biologics, aligning experienced leadership with groundbreaking science. Backed by significant seed funding and compelling preclinical data, the company is strategically positioned for its transition into a clinical-stage entity. As Commit prepares to name its first clinical candidates, the biotechnology community will be watching its progress in harnessing the complement system to redefine immunotherapy.